Amneal Pharmaceuticals Inc. has submitted a new drug application for the treatment of Parkinson’s Disease to the U.S. Food and Drug Administration (FDA). The new drug IPX203, is a novel oral formulation of carbidopa/levidopa capsules for patients suffering from Parkinson’s Disease (PD). The submission was initiated based on the promising data received from the RISE-PD Phase-3 Clinical Trial. “The RISE-PD data indicate IPX203 can offer patients a new and important treatment option that will enable them to have more “Good On” time during the day, which we believe would be a significant new benefit for Parkinson’s patients. We are working with the FDA to bring this treatment to market”, said Chintu Patel, Co-Chief Executive Officer.
Choosing the Right Patient for the Right ADC Beyond the Basics of Biomarker Testing
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed pivots from molecules to metrics. After a long run dissecting
